Alan J. Korman
Bristol-Myers Squibb (United States)
Affiliation Bristol-Myers Squibb (United States) Top Publications Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer (2012) – 12,882 citations Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer (2012) – 8,121 citations Nivolumab plus Ipilimumab in Advanced Melanoma (2013) – 4,267 citations Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in ... <a title="Alan J. Korman" class="read-more" href="https://journalsworld.com/researchers/alan-j-korman/" aria-label="Read more about Alan J. Korman">Read more</a>
Read biography ↓Biography, research & contributions
Affiliation
Bristol-Myers Squibb (United States)
Top Publications
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer (2012) - 12,882 citations
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer (2012) - 8,121 citations
- Nivolumab plus Ipilimumab in Advanced Melanoma (2013) - 4,267 citations
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates (2010) - 2,979 citations
- Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens (2014) - 2,018 citations
At a glance
- Full name
- Alan J. Korman
- ORCID
- 0000-0002-1142-8542
- OpenAlex ID
- https://openalex.org/A5036054479
Research interests
- Cancer Immunotherapy and Biomarkers, T-cell and B-cell Immunology, Immunotherapy and Immune Responses, Monoclonal and Polyclonal Antibodies Research, Immune Cell Function and Interaction
Research topics
Education
Not yet documented in this profile.
Selected research & further reading
A curated reading list, not a ranking by citation count. References use DOI metadata, matching public scholarly records or authoritative lecture sources.
See the source-linked reading and original works in the research guide above.
Citation & publication trends
Annual counts are not yet available from a verified author record. Explore the research guide above for the work itself; publication and citation totals depend on database coverage.
Source: OpenAlex · Retrieved 2026-10-08. Metrics are database-specific and are not a scientific ranking.
Most-cited linked publications
Publications matched across ORCID and OpenAlex. Citation counts are source-specific.
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer ↗2012 · New England Journal of Medicine12,882OpenAlex citations
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer ↗2012 · New England Journal of Medicine8,121OpenAlex citations
- Nivolumab plus Ipilimumab in Advanced Melanoma ↗2013 · New England Journal of Medicine4,267OpenAlex citations
- 2,979OpenAlex citations
- 2,018OpenAlex citations
Recent linked publications
Publications matched across ORCID and OpenAlex. Citation counts are source-specific.
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer ↗2012 · New England Journal of Medicine
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer ↗2012 · New England Journal of Medicine
- Nivolumab plus Ipilimumab in Advanced Melanoma ↗2013 · New England Journal of Medicine
Journals published in
No verified record links added yet.
Related publishers
No verified record links added yet.
Institutions
Current verified institution
No verified record links added yet.
Previous institutions
No verified record links added yet.
Awards & honors
Not yet documented in this profile.
Career timeline
Not yet documented in this profile.
Co-authors
No verified record links added yet.
Education & career institution links
No verified record links added yet.
Claim & manage this profile
Are you this researcher? Sign in, provide identity evidence, and request administrator approval. Editing becomes available only after approval.
Sign in to claim this profileSources & data information
Editorial review: 2026-10-08 · Last data update: 2026-10-08 00:07:10
Unknown values are left blank. Linked publications may be a subset of total works. Identity verification, data retrieval and profile ownership are separate checks.